Medincell (Euronext Paris: MEDCL) today announced that its Board of Directors will propose the appointment of Dr. Elisabeth Svanberg as an independent director at the Company’s Annual General Meeting on September 30, 2026. A highly experienced international life sciences executive, Dr. Svanberg would bring deep expertise in global pharmaceutical development, governance, executive compensation and global health as Medincell advances its next phase of growth.

Following the appointments of Dr. Pascal Touchon, Dr. Sharon Mates and Dr. Charles Kunsch since 2025, Dr. Svanberg’s proposed election would continue the Board’s deliberate renewal. Upon her election, 50% of Medincell’s Board would have been renewed since 2025, combining continuity with highly complementary international expertise spanning biopharmaceutical innovation, strategic execution, commercialization, governance and finance.

Dr. Elisabeth Svanberg MD, PhD, said: “Improving treatment adherence is one of the most important opportunities to improve healthcare today. Medincell’s long-acting technologies offer a compelling solution for patients worldwide, to meet this goal . As the Company enters a new phase of growth, I am honored to be proposed for election at the General Meeting. I look forward to working together with Medincell’s Directors and management, bringing my experience in pharmaceutical development, governance and global health to further support Medincell’s ambition to extend the impact of its innovations and create long-term value for patients and shareholders.”

Dr. Svanberg is an international life sciences executive with extensive experience across biotechnology and pharmaceuticals.

For more information, please click here: https://www.medincell.com/news/

About Medincell

medincell.com

Media gallery

About The Author
Business Wire